Targeting Inflammatory Signaling in Prostate Cancer Castration Resistance

Although castration-resistant prostate cancer (CRPC) as a whole, by its name, refers to the tumors that relapse and/or regrow independently of androgen after androgen deprivation therapy (ADT), untreated tumor, even in early-stage primary prostate cancer (PCa), contains androgen-independent (AI) PCa...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Shangwei Zhong, Changhao Huang, Zhikang Chen, Zihua Chen, Jun-Li Luo
Formato: article
Lenguaje:EN
Publicado: MDPI AG 2021
Materias:
R
Acceso en línea:https://doaj.org/article/6d80489b6ba0470e90a9af36efd096d1
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:6d80489b6ba0470e90a9af36efd096d1
record_format dspace
spelling oai:doaj.org-article:6d80489b6ba0470e90a9af36efd096d12021-11-11T17:38:04ZTargeting Inflammatory Signaling in Prostate Cancer Castration Resistance10.3390/jcm102150002077-0383https://doaj.org/article/6d80489b6ba0470e90a9af36efd096d12021-10-01T00:00:00Zhttps://www.mdpi.com/2077-0383/10/21/5000https://doaj.org/toc/2077-0383Although castration-resistant prostate cancer (CRPC) as a whole, by its name, refers to the tumors that relapse and/or regrow independently of androgen after androgen deprivation therapy (ADT), untreated tumor, even in early-stage primary prostate cancer (PCa), contains androgen-independent (AI) PCa cells. The transformation of androgen-dependent (AD) PCa to AI PCa under ADT is a forced evolutionary process, in which the small group of AI PCa cells that exist in primary tumors has the unique opportunity to proliferate and expand selectively and dominantly, while some AD PCa cells that have escaped from ADT-induced death acquire the capability to survive in an androgen-depleted environment. The adaptation and reprogramming of both PCa cells and the tumor microenvironment (TME) under ADT make PCa much stronger than primary tumors so that, currently, there are no effective therapeutic methods available for the treatment of CRPC. Many mechanisms have been found to be related to the emergence and maintenance of PCa castration resistance; in this review, we focus on the role of inflammatory signaling in both PCa cells and the TME for the emergence and maintenance of CRPC and summarize the recent advances of therapeutic strategies that target inflammatory signaling for the treatment of CRPC.Shangwei ZhongChanghao HuangZhikang ChenZihua ChenJun-Li LuoMDPI AGarticleandrogen deprivation therapy (ADT)castration-resistant prostate cancer (CRPC)inflammatory signalingnuclear factor-kappa B (NF-κB)IκB kinase (IKK)macrophageMedicineRENJournal of Clinical Medicine, Vol 10, Iss 5000, p 5000 (2021)
institution DOAJ
collection DOAJ
language EN
topic androgen deprivation therapy (ADT)
castration-resistant prostate cancer (CRPC)
inflammatory signaling
nuclear factor-kappa B (NF-κB)
IκB kinase (IKK)
macrophage
Medicine
R
spellingShingle androgen deprivation therapy (ADT)
castration-resistant prostate cancer (CRPC)
inflammatory signaling
nuclear factor-kappa B (NF-κB)
IκB kinase (IKK)
macrophage
Medicine
R
Shangwei Zhong
Changhao Huang
Zhikang Chen
Zihua Chen
Jun-Li Luo
Targeting Inflammatory Signaling in Prostate Cancer Castration Resistance
description Although castration-resistant prostate cancer (CRPC) as a whole, by its name, refers to the tumors that relapse and/or regrow independently of androgen after androgen deprivation therapy (ADT), untreated tumor, even in early-stage primary prostate cancer (PCa), contains androgen-independent (AI) PCa cells. The transformation of androgen-dependent (AD) PCa to AI PCa under ADT is a forced evolutionary process, in which the small group of AI PCa cells that exist in primary tumors has the unique opportunity to proliferate and expand selectively and dominantly, while some AD PCa cells that have escaped from ADT-induced death acquire the capability to survive in an androgen-depleted environment. The adaptation and reprogramming of both PCa cells and the tumor microenvironment (TME) under ADT make PCa much stronger than primary tumors so that, currently, there are no effective therapeutic methods available for the treatment of CRPC. Many mechanisms have been found to be related to the emergence and maintenance of PCa castration resistance; in this review, we focus on the role of inflammatory signaling in both PCa cells and the TME for the emergence and maintenance of CRPC and summarize the recent advances of therapeutic strategies that target inflammatory signaling for the treatment of CRPC.
format article
author Shangwei Zhong
Changhao Huang
Zhikang Chen
Zihua Chen
Jun-Li Luo
author_facet Shangwei Zhong
Changhao Huang
Zhikang Chen
Zihua Chen
Jun-Li Luo
author_sort Shangwei Zhong
title Targeting Inflammatory Signaling in Prostate Cancer Castration Resistance
title_short Targeting Inflammatory Signaling in Prostate Cancer Castration Resistance
title_full Targeting Inflammatory Signaling in Prostate Cancer Castration Resistance
title_fullStr Targeting Inflammatory Signaling in Prostate Cancer Castration Resistance
title_full_unstemmed Targeting Inflammatory Signaling in Prostate Cancer Castration Resistance
title_sort targeting inflammatory signaling in prostate cancer castration resistance
publisher MDPI AG
publishDate 2021
url https://doaj.org/article/6d80489b6ba0470e90a9af36efd096d1
work_keys_str_mv AT shangweizhong targetinginflammatorysignalinginprostatecancercastrationresistance
AT changhaohuang targetinginflammatorysignalinginprostatecancercastrationresistance
AT zhikangchen targetinginflammatorysignalinginprostatecancercastrationresistance
AT zihuachen targetinginflammatorysignalinginprostatecancercastrationresistance
AT junliluo targetinginflammatorysignalinginprostatecancercastrationresistance
_version_ 1718432068260593664